COVID-19 and Mucosal Immunization: Assessing Current Efforts, Challenges, and Future Opportunities for Vaccine Development

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Current Clinical Microbiology Reports

• Publication date

  2025-11-19

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1007/s40588-025-00262-z
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Intranasal HD-Ad-FS vaccine induces systemic and airway mucosal immunities against SARS-CoV-2 and systemic immunity against SARS-CoV-2 variants in mice and hamsters

  2024cited by this paper
• A single-dose intranasal live-attenuated codon deoptimized vaccine provides broad protection against SARS-CoV-2 and its variants

  2024cited by this paper
• Mucosal immunization with ChAd-SARS-CoV-2-S prevents sequential transmission of SARS-CoV-2 to unvaccinated hamsters

  2024cited by this paper
• Mucosal vaccines for SARS-CoV-2: triumph of hope over experience

  2023cited by this paper
• SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines

  2023cited by this paper
• Promises and challenges of mucosal COVID-19 vaccines

  2023cited by this paper
• Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses

  2023cited by this paper
• Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial

  2023cited by this paper
• Mucosal vaccination: onward and upward

  2023cited by this paper
• Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration.

  2023cited by this paper
• Mucosal vaccine delivery: A focus on the breakthrough of specific barriers

  2022cited by this paper
• A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern

  2022cited by this paper
• Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses

  2022cited by this paper
• Intranasal Immunization with Liposome-Displayed Receptor-Binding Domain Induces Mucosal Immunity and Protection against SARS-CoV-2

  2022cited by this paper
• A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

  2022cited by this paper
• Nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.

  2022cited by this paper
• Mucosal immunity: The missing link in comprehending SARS-CoV-2 infection and transmission

  2022cited by this paper
• Factors Limiting the Translatability of Rodent Model–Based Intranasal Vaccine Research to Humans

  2022cited by this paper
• Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology

  2022cited by this paper
• Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines

  2022influential reference
• Memory B cell diversity: insights for optimized vaccine design

  2022cited by this paper
• Oral and intranasal vaccines against SARS‐CoV‐2: Current progress, prospects, advantages, and challenges

  2022cited by this paper
• Strategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases

  2022cited by this paper
• Lung-resident memory B cells established after pulmonary influenza infection display distinct transcriptional and phenotypic profiles

  2022cited by this paper
• Intranasal COVID-19 vaccines: From bench to bed

  2022cited by this paper
• mRNA-based SARS-CoV-2 vaccination is associated with reduced ICU admission rate and disease severity in critically ill COVID-19 patients treated in Switzerland

  2022cited by this paper
• Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse

  2021cited by this paper
• Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

  2021cited by this paper
• Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization

  2021cited by this paper
• Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses

  2021cited by this paper
• Human mucosal tissue-resident memory T cells in health and disease

  2021cited by this paper
• OUP accepted manuscript

  2021cited by this paper
• Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity.

  2021cited by this paper
• Tissue resident memory T cells in the respiratory tract

  2021cited by this paper
• Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative

  2021cited by this paper
• Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

  2021cited by this paper
• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

  2021cited by this paper
• Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2

  2021cited by this paper
• Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management

  2021cited by this paper
• COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform

  2021cited by this paper
• Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models

  2021cited by this paper
• Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

  2021cited by this paper
• Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman Primates

  2021cited by this paper
• Mucosal and transdermal vaccine delivery strategies against COVID-19

  2021cited by this paper
• Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?

  2021cited by this paper
• Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques

  2021cited by this paper
• ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7

  2021cited by this paper
• Development of an inactivated vaccine candidate for SARS-CoV-2

  2020cited by this paper
• Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects

  2020cited by this paper
• The Effects of Secretory IgA in the Mucosal Immune System

  2020influential reference
• A new coronavirus associated with human respiratory disease in China

  2020cited by this paper
• Coronavirus disease 2019 (COVID-19): a clinical update

  2020cited by this paper
• Secretory IgA in Mucosa of Pharynx and Larynx Plays an Important Role against Influenza A Virus Infection in Kidney Yang Deficiency Syndrome Model

  2020cited by this paper
• Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

  2020cited by this paper
• Immunological considerations for COVID-19 vaccine strategies

  2020cited by this paper
• Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection

  2020cited by this paper
• Cold-Adapted Live Attenuated SARS-Cov-2 Vaccine Completely Protects Human ACE2 Transgenic Mice from SARS-Cov-2 Infection

  2020cited by this paper
• A systematic review of SARS-CoV-2 vaccine candidates

  2020cited by this paper
• The role of dysregulated immune responses in COVID-19 pathogenesis

  2020cited by this paper
• Analysis of respiratory and systemic immune responses in COVID-19 reveals mechanisms of disease pathogenesis

  2020cited by this paper
• Adjuvants for Coronavirus Vaccines

  2020cited by this paper
• A single intranasal or intramuscular immunization with chimpanzee adenovirus vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters

  2020cited by this paper
• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

  2020cited by this paper
• Recent Insights into Cellular Crosstalk in Respiratory and Gastrointestinal Mucosal Immune Systems

  2020cited by this paper
• Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

  2020cited by this paper
• Mucosal vaccines and technology

  2019cited by this paper
• Tissue-Resident T Cells and Other Resident Leukocytes.

  2019cited by this paper
• IgA: Structure, Function, and Developability

  2019cited by this paper
• IgA and FcαRI: Pathological Roles and Therapeutic Opportunities

  2019cited by this paper
• The establishment of resident memory B cells in the lung requires local antigen encounter

  2018cited by this paper
• Immunological memory cells

  2018cited by this paper
• Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology

  2017cited by this paper
• Memory B Cells of Mice and Humans.

  2017cited by this paper
• Trigger-happy resident memory CD4+ T cells inhabit the human lungs

  2017cited by this paper
• Current state and challenges in developing oral vaccines.

  2017cited by this paper
• Programs for the persistence, vigilance and control of human CD8+ lung-resident memory T cells

  2016cited by this paper
• Early local immune defences in the respiratory tract

  2016cited by this paper
• Tissue-resident memory T cells: local specialists in immune defence

  2015cited by this paper
• Resident memory CD8 T cells trigger protective innate and adaptive immune responses

  2014cited by this paper
• Diagnostic Significance of Reduced IgA in Children

  2014cited by this paper
• Buccal and sublingual vaccine delivery

  2014cited by this paper
• Overview of orchestration of CD4+ T cell subsets in immune responses.

  2014cited by this paper
• Mucosal vaccines

  2014cited by this paper
• Challenges in mucosal vaccines for the control of infectious diseases.

  2014cited by this paper
• Mechanisms of Action of Adjuvants

  2013cited by this paper
• MUCOSAL IMMUNITY AND VACCINES

  2013cited by this paper
• Recent progress in mucosal vaccine development: potential and limitations

  2012cited by this paper
• Mucosal vaccination--an old but still vital strategy.

  2012cited by this paper
• New insights in mucosal vaccine development.

  2012cited by this paper
• Secretory IgA's complex roles in immunity and mucosal homeostasis in the gut

  2011cited by this paper
• Structure and function relationships in IgA

  2011cited by this paper
• Vaccine adjuvants: putting innate immunity to work.

  2010cited by this paper
• Mucins in the mucosal barrier to infection

  2008cited by this paper
• Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection1

  2008cited by this paper
• The Central Memory CD4+ T Cell Population Generated during Leishmania major Infection Requires IL-12 to Produce IFN-γ1

  2008cited by this paper
• The regulation of IgA class switching

  2008cited by this paper
• Mucosal Immunization with Surface-Displayed Severe Acute Respiratory Syndrome Coronavirus Spike Protein on Lactobacillus casei Induces Neutralizing Antibodies in Mice

  2006cited by this paper
• Mucosal delivery of vaccines in domestic animals.

  2006cited by this paper
• Buccal bioadhesive drug delivery--a promising option for orally less efficient drugs.

  2006cited by this paper
• The distribution of oral mucosal pH values in healthy saliva secretors.

  2006cited by this paper

• No citing papers are available for this paper.